Dementia with Lewy Bodies

Slide 1 · Dementia with Lewy Bodies

Clinicopathologic correlations of α-synuclein disease

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Define the clinicopathologic DLB phenotype and its relation to Parkinson disease.

Recognize α-synuclein–containing Lewy bodies and Lewy neurites.

Explain characteristic distribution, morphology and limitations of correlation.

Distinguish related neurodegenerative pathologies using the supplied textbook.

Slide 3 · DLB in the neurodegenerative-disease framework

Synucleinopathy

Lewy pathology

Dementia phenotype

DLB belongs to the α-synuclein-associated neurodegenerative disorders.

Its pathology overlaps the Parkinson disease (PD) spectrum.

Clinical expression prominently includes cognitive and neuropsychiatric abnormalities.

Slide 4 · What does “dementia with Lewy bodies” name?

Neuronal aggregation

Cortical + brainstem involvement

Clinical dementia

The term highlights widespread neuronal Lewy bodies in cortex and brainstem.

Lewy bodies contain aggregated α-synuclein.

A clinical diagnosis and a pathologic lesion are related, but not interchangeable.

Slide 5 · PD and DLB form a disease spectrum

Parkinson-predominant

Dementia-predominant

Robbins treats PD and DLB as related expressions of Lewy body disease.

Both share genetic alterations and α-synuclein molecular conformation.

The relative prominence and sequence of cognitive versus motor signs differ.

Compare the clinical or pathologic level being described—not merely the names.

Slide 6 · Clinical pattern: Three emphasized features

Fluctuation

Visual hallucinations

Frontal signs

Fluctuating course of cognitive dysfunction.

Visual hallucinations.

Prominent frontal signs.

Slide 7 · Fluctuating cognition is part of the phenotype

A fluctuating course is specifically highlighted in the Robbins description.

A single observation may incompletely characterize the cognitive state.

Variation over time is relevant to clinical description.

Slide 8 · Visual hallucinations are a major clinical clue

Visual hallucinations are named among the characteristic features.

They accompany a dementing illness rather than defining the lesion by themselves.

Pathologic identification still depends on the α-synuclein disease context.

Slide 9 · “Frontal signs” describe the cognitive profile

Prominent frontal signs are included clinical description.

They identify frontal-system dysfunction at the bedside.

The cited source does not specify a formal executive-test threshold.

Slide 10 · The motor–cognitive axis is not fixed

Motor symptoms first

Dementia first

Some patients have a motor-first PD phenotype before dementia.

In others dementia is the initial symptom, with motor findings later.

Thus a uniform sequence cannot describe the whole spectrum.

Compare the clinical or pathologic level being described—not merely the names.

Slide 11 · Motor-first trajectory

PD motor phenotype

Later cortical pathology

Cognitive impairment

An established PD syndrome can later include cognitive impairment.

The textbook proposes subsequent cortical involvement in some individuals.

Aggregation “spread” is a suggested mechanism, not a proven individual timeline.

Slide 12 · Dementia-first trajectory

Dementia phenotype

Motor signs emerge

Shared synucleinopathy

Dementia may occur before recognizably parkinsonian motor symptoms.

Robbins interprets this as compatible with a different direction of disease involvement.

Initial presentation does not alone map microscopic propagation.

Slide 13 · Two trajectories: One disease family

Motor-first presentation

Dementia-first presentation

Cognition later prominent

Motor signs later emerge

Two documented orders of presentation; Neither establishes a compulsory microscopic route.

Slide 14 · A percentage must retain its denominator

Observation ≠ general prevalence estimate

Approximately 10%–15% of individuals with PD develop dementia.

The reported proportion relates to people with PD description.

It is NOT an estimate of DLB prevalence in the community.

Slide 15 · Dementia in PD can have mixed pathology

Cognitive impairment

Evaluate pathology

Lewy / Alzheimer / mixed

Some people with dementia also have Alzheimer pathologic changes.

Other degenerative diseases are less frequent concurrent explanations.

The dominant histologic correlate varies among affected individuals.

Slide 16 · Normal α-synuclein: The starting point

Synaptic protein

Misfolding / aggregation

Neuronal inclusions

α-Synuclein is an abundant lipid-binding protein normally localized to synapses.

The SNCA gene encodes α-synuclein.

Disease is associated with abnormal aggregation rather than mere protein presence.

Slide 17 · Why protein aggregation matters

α-synuclein species

Aggregates / oligomers

Neuronal dysfunction

Lewy bodies are formed from aggregated α-synuclein.

The adjacent PD section suggests small oligomeric aggregates may be particularly toxic.

The exact link from cortical inclusions to dementia remains unclear.

Slide 18 · Lewy bodies versus Lewy neurites

Neuronal soma

Neuronal process

Lewy bodies are intraneuronal cytoplasmic inclusions.

Lewy neurites are abnormal neuronal processes containing aggregated α-synuclein.

Both lesions contribute to the recognizable synucleinopathy pattern.

Compare the clinical or pathologic level being described—not merely the names.

Slide 19 · Anatomic distribution of Lewy pathology

Brainstem

Limbic structures

Cerebral cortex

DLB may contain widespread Lewy bodies in cerebral cortex and brainstem.

The brainstem component overlaps the PD distribution.

The cortical component is relevant to the dementia presentation.

Slide 20 · Proposed ascending aggregate distribution

Medulla / brainstem

Limbic structures

Neocortex

The PD parent section describes aggregates from medulla to brainstem, limbic areas and neocortex.

This is a proposed disease-progression pattern, not a mandatory DLB sequence.

Anatomic involvement is broader than substantia nigra alone.

Slide 21 · Possible neuron-to-neuron transfer

Donor neuron

Extracellular aggregate

Recipient neuron

Aggregated α-synuclein can be released and taken up by another neuron.

This finding supports a prion-like propagation hypothesis.

A mechanistic hypothesis should not be presented as a directly observed patient trajectory.

Slide 22 · Why “prion-like” requires qualification

The term describes possible templated propagation of a misfolded protein.

The PD section uses supporting experimental evidence for inter-neuronal movement.

The source does not claim that DLB is an infectious prion disease.

Slide 23 · A different clinical direction may occur

Motor-first presentation

Dementia-first presentation

Cognition later prominent

Motor signs later emerge

Two documented orders of presentation; Neither establishes a compulsory microscopic route.

Slide 24 · Synuclein pathology has multiple compartments

Cell body

Neurite

Glia (MSA)

Neuronal cell bodies contain Lewy bodies.

Neuronal processes contain Lewy neurites.

The source also distinguishes the oligodendroglial α-synuclein inclusions of MSA.

Slide 25 · Gross pathology: Substantia nigra depigmentation

Normal pigmentation

Neuronal loss

Visible pallor

Depigmentation of the substantia nigra is typically present in DLB.

The PD section attributes pallor to loss of pigmented catecholaminergic neurons.

This finding reflects degeneration, not a specific measurement of cognitive severity.

Slide 26 · Gross pathology: Locus ceruleus changes

Loss of pigmentation also involves the locus ceruleus.

This is a brainstem nucleus within the broader Lewy pathology distribution.

Gross examination therefore may show brainstem findings even when cortical atrophy is limited.

Slide 27 · Relatively preserved cerebral cortex

Gross cortex relatively preserved

Microscopic Lewy pathology

The cortical architecture is often relatively preserved on gross inspection.

This contrasts with the severity of cognitive disturbance in DLB.

Cortical synuclein pathology may be present despite limited gross abnormalities.

Compare the clinical or pathologic level being described—not merely the names.

Slide 28 · Relatively preserved hippocampus

The hippocampus is listed among grossly relatively preserved structures.

Gross preservation does not exclude abnormal protein aggregates.

Alzheimer-type concomitant pathology remains possible in individual cases.

Slide 29 · Relatively preserved amygdala

The amygdala is another area of relative gross preservation noted by Robbins.

The comparison concerns gross pathology, not absence of microscopic disease.

Interpret preserved appearance within the wider proteinopathy context.

Slide 30 · Gross pathology does not reveal all lesions

Macroscopic observation

Protein-level detection

Brainstem depigmentation is an informative macroscopic clue.

Relatively preserved cortex, hippocampus and amygdala can coexist with dementia.

Microscopic staining is essential to localize α-synuclein pathology.

Compare the clinical or pathologic level being described—not merely the names.

Slide 31 · Lewy body: Routine-light-microscopy profile

Schematic neuronal soma

The PD parent section describes eosinophilic cytoplasmic inclusions.

Inclusions can be round to elongated, single or multiple.

A dense central core and surrounding pale halo may be visible.

Slide 32 · The core–halo appearance is a pattern, not a requirement

Schematic neuronal soma

Classical brainstem Lewy bodies can display dense core and pale halo.

Cortical Lewy bodies are less morphologically distinctive.

Absence of a textbook-looking inclusion in a single field is not definitive.

Slide 33 · Ultrastructural composition

α-synuclein

Filamentous aggregates

Lewy body architecture

At ultrastructural level, Lewy bodies contain fine filaments.

Filaments are densely packed centrally and looser at the periphery.

α-Synuclein is a major constituent.

Slide 34 · Cortical Lewy bodies may be subtle

Brainstem inclusion

Subtle cortical inclusion

Cortical inclusions are less distinctive than brainstem Lewy bodies.

They nevertheless contain predominantly α-synuclein.

Routine morphology alone may underestimate cortical disease.

Compare the clinical or pathologic level being described—not merely the names.

Slide 35 · α-Synuclein immunohistochemistry

Tissue section

α-synuclein stain

Bodies + neurites

α-synuclein immunostaining as a way to detect lesions.

Staining reveals neuronal Lewy inclusions and Lewy neurites.

A positive lesion demonstrates protein pathology; It does not alone prove a unique clinical syndrome.

Slide 36 · Lewy neurites expand the observable lesion set

Lewy body

Lewy neurite

Lewy neurites are abnormal neuronal processes containing aggregates.

They may be highlighted by α-synuclein immunohistochemistry.

Counting only conspicuous somatic inclusions misses a component of pathology.

Compare the clinical or pathologic level being described—not merely the names.

Slide 37 · The cortical inclusion-burden paradox

Inclusion burden ≠ cognitive impairment severity

Cortical Lewy body burden is usually low.

Cognitive impairment can nevertheless be pronounced.

A simple inclusion count may fail to explain clinical severity.

Slide 38 · Do not overstate the mechanism of dementia

The precise mechanism of cognitive disturbance is not established in the source.

Aggregation, neuroanatomic spread and mixed pathology are plausible contexts.

Avoid presenting a single causal pathway as definitively explaining cognition.

Slide 39 · Clinical motor syndrome in the parent PD section

Bradykinesia

Rigidity

Tremor

PD causes a hypokinetic motor disorder involving the nigrostriatal system.

Key motor manifestations include bradykinesia, rigidity and tremor.

The motor phenotype may eventually coexist with dementia.

Slide 40 · Nigrostriatal mechanism connects anatomy to movement

Nigral neuron loss

Striatal dopamine loss

Hypokinetic signs

Degeneration of substantia nigra dopaminergic neurons reduces striatal dopamine.

This deficit contributes to the characteristic motor syndrome.

The same brainstem pathology may appear in the DLB spectrum.

Slide 41 · Symptomatic dopamine replacement: A limitation

L-DOPA

Dopamine restoration

Motor improvement ≠ cure

The PD section explains why l-DOPA can improve motor symptoms.

Dopamine replacement does not stop disease progression.

Symptomatic motor response is not an assay of cortical Lewy body burden.

Slide 42 · SNCA illustrates a primary aggregation mechanism

SNCA alteration

α-synuclein dysregulation

Aggregate formation

SNCA encodes α-synuclein.

Rare point mutations or increased gene dosage can cause inherited PD.

The genetic findings connect protein dysregulation to Lewy pathology.

Slide 43 · Mitochondrial quality control: PINK1–Parkin

Damaged mitochondrion

PINK1 → Parkin

Mitophagy

PINK1 identifies dysfunctional mitochondria and activates Parkin recruitment/signaling.

Parkin-mediated ubiquitination marks mitochondrial proteins for mitophagy.

Mutations disrupting this pathway support mitochondrial dysfunction in PD pathogenesis.

Slide 44 · Lysosomal biology: GBA1 context

GBA1 impairment

Lysosomal dysfunction

α-synuclein handling

GBA1 encodes glucocerebrosidase, a lysosomal enzyme.

Heterozygous pathogenic variants increase PD risk in the source discussion.

This supports lysosomal–autophagic dysfunction as a mechanism related to protein clearance.

Slide 45 · LRRK2 biology is not fully resolved

LRRK2 kinase

Rab phosphorylation

Unresolved disease link

Certain LRRK2 variants increase kinase activity and cause PD.

The parent section implicates abnormal phosphorylation of Rab proteins.

The causal bridge to α-synuclein accumulation remains uncertain.

Slide 46 · Why parent PD mechanisms matter to DLB

Shared genetic context

Shared fold

Different phenotype

PD and DLB share many genetic alterations.

They also have the same α-synuclein molecular fold.

Specific gene-by-gene DLB risk estimates are not provided in the supplied DLB passage.

Slide 47 · Alzheimer disease is a key pathologic comparator

Alzheimer: Aβ + tau

DLB: α-synuclein

Alzheimer disease is associated with amyloid-β plaques and tau neurofibrillary tangles.

DLB is distinguished by neuronal α-synuclein inclusions.

The two processes can coexist rather than being mutually exclusive.

Compare the clinical or pathologic level being described—not merely the names.

Slide 48 · Frontotemporal degenerations: Different proteins

FTLD: Tau / TDP-43

DLB: α-synuclein

FTLD categories include tau-associated and TDP-43-associated disorders.

These molecular lesions differ from predominant α-synuclein Lewy pathology.

Dementia phenotype alone cannot specify the aggregated protein.

Compare the clinical or pathologic level being described—not merely the names.

Slide 49 · Multiple system atrophy: Same protein, different cell

PD / DLB: Neurons

MSA: Oligodendrocytes

MSA is another α-synucleinopathy.

Its defining inclusions are predominantly cytoplasmic aggregates in oligodendrocytes.

The cellular compartment contrasts with neuronal Lewy inclusions in PD/DLB.

Compare the clinical or pathologic level being described—not merely the names.

Slide 50 · Distinct α-synuclein molecular conformations

PD fold

DLB fold: Shared with PD

MSA fold: Distinct

A shared α-synuclein molecular fold in PD and DLB.

That fold differs from the α-synuclein fold in MSA.

Therefore protein identity alone does not capture the whole proteinopathy distinction.

Slide 51 · Diagnostic pathology: Identify protein and compartment

Lesion / phenotype

Predominant compartment

Interpretation

Lewy bodies / neurites

Neuronal

PD/DLB spectrum

Glial α-synuclein

Oligodendrocytes

MSA

Aβ plaques; Tau tangles

Extracellular / neuronal

Alzheimer pathology

Slide 52 · Clinicopathologic comparison: Three phenotypes

Disorder

Clinical emphasis

Pathologic context

Parkinson disease

Motor-predominant

Nigrostriatal degeneration

Dementia with Lewy bodies

Cognitive + behavioral

Cortical + brainstem Lewy bodies

Multiple system atrophy

Motor + ataxia + autonomic

Oligodendroglial inclusions

Slide 53 · Pathology exercise: A pigmented nucleus becomes pale

Observation: The substantia nigra is visibly depigmented.

Interpretation: Loss of pigmented catecholaminergic neurons is implicated.

Next question: Which protein inclusion supports Lewy-spectrum pathology?

Discussion prompt — interpret observations without inventing additional data

Slide 54 · Case exercise: Motor symptoms predate dementia

Vignette: Longstanding hypokinetic parkinsonism, followed by cognitive decline.

The motor-first course is compatible with the PD–DLB spectrum.

Discuss why Alzheimer-type copathology remains possible.

Discussion prompt — interpret observations without inventing additional data

Slide 55 · Case exercise: Dementia precedes motor signs

Vignette: Fluctuating dementia with visual hallucinations; Motor signs emerge later.

The order resembles the dementia-first phenotype in the source.

Would this temporal order alone establish an anatomic propagation route?

Discussion prompt — interpret observations without inventing additional data

Slide 56 · Case exercise: Cortical Lewy body count is low

Vignette: Pronounced dementia, relatively preserved cortex and few cortical Lewy bodies.

The mismatch is consistent with the source description.

Explain why a low inclusion count does not invalidate clinical disease.

Discussion prompt — interpret observations without inventing additional data

Slide 57 · Case exercise: Neuronal versus glial inclusions

Specimen A: Neuronal α-synuclein Lewy bodies and Lewy neurites.

Specimen B: Oligodendroglial cytoplasmic α-synuclein inclusions.

Explain which pattern aligns with PD/DLB and which with MSA.

Discussion prompt — interpret observations without inventing additional data

Slide 58 · Integrated synthesis: Four defensible statements

PD and DLB belong to a related α-synuclein disease spectrum.

Cortical and brainstem neuronal Lewy pathology characterizes DLB.

The clinical sequence of dementia and motor signs varies.

The mechanism linking low cortical inclusion burden to severe dysfunction remains incompletely understood.

Slide 59 · Integrated synthesis: Morphology and interpretation

Look for substantia nigra and locus ceruleus depigmentation.

Expect relative gross preservation of cortex, hippocampus and amygdala.

Recognize inclusions and neurites with α-synuclein staining.

Distinguish protein identity, cellular localization and possible copathology.

Slide 60 · Textbook sources and scope

Primary source: Robbins, Cotran & Kumar, Pathologic Basis of Disease, 11th ed. (2026).

DLB section: Chapter 28, pp. 1168–1169.

Supporting parent context: Parkinson disease, pp. 1166–1168; Alzheimer disease and MSA/FTLD sections.

The source excerpt does not provide formal DLB diagnostic criteria or management recommendations.